Clinical trials: Lymphoid
Leukemia, Lymphoma
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Aldesleukin may stimulate natural killer cells to kill cancer cells. Treating natural killer cells with aldesleukin in the laboratory may help the natural killer cells kill more cancer cells when they are put back in…
- Trial name
- NCT00625729
- Testing
- aldesleukin, allogeneic natural killer cells, rituximab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Lymphoma
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00002502
- Testing
- busulfan, cyclophosphamide, cytarabine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
To learn if the combination of LOXO-305 (pirtobrutinib) and venetoclax can help to control previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
- Trial name
- NCT05317936
- Testing
- Pirtobrutinib, Venetoclax
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Trial name
- NCT00265928
- Testing
- bortezomib, rituximab, antibody therapy
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Virginia
CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
This is a study of CDX-1127, a therapy that targets the immune system and may act to promote anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias and lymphomas), as well as patients with…
- Conditions
- CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma)
- Trial name
- NCT01460134
- Testing
- CDX-1127
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- Celldex Therapeutics
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134004
- Testing
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR
This research study is for subjects that are receiving a bone marrow transplant. As part of the transplant subjects will receive stem cells from a donor who has agreed to donate stem cells for them.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- TAR (NCT01611298)
- Testing
- Tetanus
- Where
- 2 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Robert Krance
Leukemia, Lymphoblastic
ETOILE : A Feasibility Study in Pediatric Patient Education
Feasibility study of a therapeutic education program for the patient and his carers, intended for children suffering from acute lymphoblastic leukemia or having received an allograft of hematopoietic stem cells in the pediatric…
- Trial name
- ETOILE (NCT04399863)
- Testing
- ETOILE therapeutic education
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Relapsed or Refractory Acute Lymphoblastic Leukemia
Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)
This study is a Phase II, single-arm, open-label, non-randomized, dose-escalation clinical trial to evaluate the efficacy and safety of ssCART-19 Cell Injection in the treatment of patients with CD19 positive Relapsed or…
- Trial name
- NCT06367114
- Testing
- ssCART-19, Fludarabine, Cyclophosphamide
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
This phase Ib/II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization.
- Conditions
- Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Monoclonal B-Cell Lymphocytosis
- Trial name
- NCT04439006
- Testing
- Best Practice, Ibrutinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Jennifer Woyach
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
The purpose of this study is to explore the effect of G-CSF combination with GM-CSF on prevention and treatment of infection in children with malignant tumor.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT02933333
- Testing
- GM-CSF, G-CSF, GM-CSF and G-CSF
- Where
- 7 sites in China
- Volunteers
- 405 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Adult T Cell Leukemia/Lymphoma
Lenalidomide in HTLV-1 Adult T-Cell Leukemia
This is a research study for subjects who have been diagnosed with Adult T cell Leukemia/Lymphoma, a rare and aggressive peripheral T cell neoplasm caused by the virus HTLV1.
- Trial name
- NCT01274533
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia University
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of iodine I 131 monoclonal antibody BC8 when given before autologous stem cell transplant in treating patients with Hodgkin lymphoma or non-Hodgkin lymphoma that has…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT00860171
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Iodine I 131 Monoclonal Antibody BC8, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed or Refractory Chronic Lymphocytic Leukemia
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction
Ibrutinib, a first-in-class Bruton Tyrosine kinase (BTK) inhibitor, has become an established treatment in relapsed/refractory chronic lymphocytic leukemia (CLL).
- Trial name
- IDA53 (NCT03734198)
- Testing
- Ibrutinib, Daratumumab
- Where
- 24 sites in France
- Volunteers
- 29 people
- Sponsor
- French Innovative Leukemia Organisation
Leukemia, Lymphoma
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
Background: Leukapheresis is a procedure to separate and collect white blood cells. It is the first step in a treatment called CAR (chimeric antigen receptor) T-cell therapy.
- Conditions
- Leukemia, Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03226704
- Testing
- Leukapheresis
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Down Syndrome, Acute Lymphoblastic Leukemia
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
To evaluate the outcome of a prednisolone and low dose methotrexate based protocol in Down syndrome children with ALL (DS-ALL) in an Asia-wide study.
- Conditions
- Down Syndrome, Acute Lymphoblastic Leukemia, Childhood Cancer
- Trial name
- NCT03286634
- Testing
- Daunorubicin, Prednisolone, Vincristine
- Where
- 10 sites in Hong Kong, Japan and 4 more
- Volunteers
- 60 people
- Sponsor
- National Hospital Organization Nagoya Medical Center
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Major Complication Rate in Cancer Patients With Neutropenic Fever Potentially Eligible for a Hospital at Home Program
This study investigates the major complication rate in cancer patients potentially eligible for a hospital at home program for management of neutropenic fever.
- Trial name
- NCT04557709
- Testing
- Medical Chart Review
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia ALL
Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL
This research study is evaluating a drug called ribociclib (LEE011) given in combination with everolimus and other standard of care chemotherapy drugs as a possible treatment for relapsed or refractory ALL.
- Trial name
- NCT03740334
- Testing
- Ribociclib, Dexamethasone, Everolimus
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Lymphoblastic Leukemia
A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
- Trial name
- NCT00774332
- Testing
- CODOX-M
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Cooperative Study Group A for Hematology
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
This phase I trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with cytarabine or vincristine liposomal in treating participants with acute leukemia that has come back or has…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Myelodysplastic/Myeloproliferative Neoplasm, Philadelphia Chromosome Positive
- Trial name
- NCT03519984
- Testing
- Cytarabine, Laboratory Biomarker Analysis, Recombinant EphB4-HSA Fusion Protein
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Southern California
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.